Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly misleading investors regarding the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious health risk in premature infants [1][4]. Group 1: Lawsuit Details - The class action lawsuit is filed in the United States District Court for the Southern District of New York on behalf of investors who purchased Reckitt securities between January 13, 2021, and July 28, 2024 [1]. - Investors have until August 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Reckitt failed to adequately warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants consuming its formula [3][4]. Group 2: Allegations Against Reckitt - The lawsuit alleges that Reckitt made misleading statements and omissions regarding its business, financial condition, and prospects during the class period [4]. - Specific allegations include failing to disclose the risks associated with Enfamil, the potential impact on sales, and the exposure to legal claims [4]. - As a result of these omissions, Reckitt's positive statements about its business were deemed materially false and misleading [4]. Group 3: Company Background - Reckitt is a UK-based global consumer goods company facing over 500 product liability lawsuits related to its infant formula [3]. - The lawsuits claim that Reckitt and its competitor Abbott Laboratories did not adequately warn about the risks associated with their cow milk-based formulas [3]. Group 4: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors in this class action lawsuit and encourages affected individuals to reach out for more information [1][5]. - The firm specializes in representing individual and institutional investors in complex litigation [6].

Company Overview - Reckitt Benckiser Group PLC (RBGLY) currently holds a Momentum Style Score of B, indicating potential for strong performance based on recent trends [3][12] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned favorably in the market [4][12] Price Performance - Over the past week, RBGLY shares have increased by 11.73%, matching the performance of the Zacks Soap and Cleaning Materials industry [6] - In the last month, RBGLY's price change is 8.09%, again in line with the industry's performance [6] - For longer-term metrics, RBGLY shares have risen 15.8% over the past three months and 41.39% over the last year, outperforming the S&P 500, which increased by 14.12% and 16.19% respectively [7] Trading Volume - The average 20-day trading volume for RBGLY is 285,846 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, three earnings estimates for RBGLY have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.92 to $0.94 [10] - For the next fiscal year, three estimates have also moved upwards without any downward revisions [10]

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt Benckiser Group plc made false statements regarding the safety of its cow's milk-based formula, Enfamil, particularly concerning the increased risk of necrotizing enterocolitis (NEC) in preterm infants [2]. - It is alleged that these false statements misled investors about the company's sales performance and exposure to legal claims, thus affecting the perceived business operations and prospects of Reckitt Benckiser [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, ensuring no financial obligation to participate [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm is recognized as one of the top securities litigation firms in the United States, ranking in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC's American Depositary Shares (ADSs) of the upcoming lead plaintiff deadline for a class action lawsuit, indicating potential compensation for affected investors [1][2]. Group 1: Class Action Details - The class action pertains to ADS purchases made between January 13, 2021, and July 28, 2024, with a lead plaintiff deadline set for August 4, 2025 [1]. - Investors who purchased Reckitt ADSs may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [1]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success and recognition in this field [3]. - The firm has achieved significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements [3]. Group 3: Case Allegations - The lawsuit alleges that Reckitt failed to inform investors about the increased risk of necrotizing enterocolitis (NEC) in preterm infants due to its cow's milk-based formula, Enfamil, which misled investors regarding the company's business prospects [4]. - The claims suggest that Reckitt's positive statements about its operations were materially false and misleading, leading to investor damages when the true information became public [4].

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Reckitt's cow's milk-based formula, Enfamil, increased the risk of preterm infants developing NEC, which was not disclosed [2] - It is alleged that the defendants' positive statements regarding Reckitt's business and sales were materially false and misleading due to the undisclosed risks and potential legal claims [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating a no-cost participation model [3] Group 3: Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its Enfamil formula, which is linked to increased risks for preterm infants [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from January 13, 2021, to July 28, 2024 [1]. - The allegations include that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of developing NEC in preterm infants, which was not disclosed [1]. - The lawsuit claims that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of RBGLY during the specified timeframe are encouraged to register for the class action by August 4, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that affected investors between January 13, 2021, and July 28, 2024 [1][2] Group 1: Allegations - The lawsuit claims that Reckitt Benckiser Group plc made false statements regarding the safety of its cow's milk-based formula, Enfamil, particularly concerning the increased risk of necrotizing enterocolitis (NEC) in preterm infants [2] - It is alleged that these false statements misrepresented the impact on Reckitt's sales of Enfamil and the company's exposure to legal claims [2] - The defendants' positive statements about the company's business and prospects were claimed to be materially false and misleading [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly misleading investors regarding the risks associated with its cow's milk-based formula, Enfamil, during the class period from January 13, 2021, to July 28, 2024 [1][4]. Company Overview - Reckitt Benckiser Group plc is a UK-based global consumer goods company facing over 500 state and federal product liability lawsuits related to its cow's milk-based formula, Enfamil, and its competitor Abbott Laboratories' Similac [3]. Legal Allegations - The class action lawsuit claims that Reckitt made misleading statements and omissions about its business and financial condition, specifically failing to disclose the increased risk of necrotizing enterocolitis (NEC) for preterm infants consuming its formula [4]. - The lawsuit alleges that Reckitt did not adequately warn investors about the potential impact on sales and legal exposure related to the NEC risk associated with its products [4].

Core Viewpoint - Reckitt Benckiser Group PLC is facing a class action lawsuit from investors due to alleged misleading statements and failure to disclose health risks associated with its Enfamil infant formula, leading to significant stock price declines [3][4][5]. Group 1: Class Action Details - The class action represents investors who purchased Reckitt Benckiser securities between January 13, 2021, and July 28, 2024, with a deadline for filing a lead plaintiff motion set for August 4, 2025 [1]. - The lawsuit claims that Reckitt Benckiser did not adequately warn consumers and investors about the increased risk of Necrotizing Enterocolitis (NEC) for preterm infants consuming its cow's milk-based formula [3]. Group 2: Legal Outcomes and Financial Impact - A jury verdict on March 15, 2024, found Mead Johnson negligent, resulting in a $60 million award for failing to warn about NEC risks, which caused Reckitt Benckiser's American Depositary Shares (ADSs) to drop nearly 14% [4]. - Following a related case on July 29, 2024, where a Missouri jury awarded $495 million in damages over NEC caused by a competing formula, Reckitt Benckiser's ADSs fell nearly 9% [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit alleging misleading statements related to the company's cow's milk-based formula, Enfamil, which may have increased health risks for preterm infants [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from January 13, 2021, to July 28, 2024 [1]. - The complaint claims that Reckitt failed to disclose that preterm infants were at an increased risk of developing NEC from consuming Enfamil [1]. - It is alleged that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of August 4, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].